Previous Close | 20.04 |
1-Year Change | -20.41% |
6-Months Change | 30.13% |
3-Months Change | 17.67% |
Moving Avg (50d) | 17.939 |
Moving Avg (200d) | 16.518 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.29M |
Beta (3-Years) | 1.05 |
Revenue Growth (ttm) | 23.54% |
Net Profit Margin (ttm) | -23.55% |
Return On Assets (ttm) | -23.53% |
EPS (ttm) | -648.43 |
PE Ratio (ttm) | -0.03 |
Dividend Yield | % |
Asset Description: | ACADIA Pharmaceuticals Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2025-02-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
19.639 | 19.038 | 18.637 | 18.036 | 17.034 | 16.032 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California. Wikipedia